NASDAQ: DBVT
Dbv Technologies Sa Stock Forecast, Predictions & Price Target

Analyst price target for DBVT

Based on 2 analysts offering 12 month price targets for Dbv Technologies Sa

Min Forecast
$10.00+12.23%
Avg Forecast
$22.50+152.53%
Max Forecast
$35.00+292.82%

Should I buy or sell DBVT stock?

Based on 2 analysts offering ratings for Dbv Technologies Sa.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DBVT stock forecasts and price targets.

DBVT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2024-10-24

1 of 1

Forecast return on equity

Is DBVT forecast to generate an efficient return?

Company
-1,250.13%
Industry
153.19%
Market
81.87%
DBVT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DBVT forecast to generate an efficient return on assets?

Company
-521.45%
Industry
36.07%
DBVT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DBVT earnings per share forecast

What is DBVT's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$5.45
Avg 2 year Forecast
-$5.30
Avg 3 year Forecast
-$2.50

DBVT revenue forecast

What is DBVT's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$5.4M+30.57%
Avg 2 year Forecast
$6.0M+43.58%
Avg 3 year Forecast
$17.5M+321.1%
DBVT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DBVT revenue growth forecast

How is DBVT forecast to perform vs Biotechnology companies and vs the US market?

Company
55.64%
Industry
65.48%
Market
10.37%
DBVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DBVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DBVT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DBVT$8.91$22.50+152.53%Buy
LSB$1.28N/AN/A
AVIR$2.86$6.00+109.79%Hold
CMPX$1.78$15.67+780.17%Strong Buy
ABEO$4.92$16.00+225.20%Strong Buy

Dbv Technologies Sa Stock Forecast FAQ

Is Dbv Technologies Sa Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: DBVT) stock is to Buy DBVT stock.

Out of 2 analysts, 0 (0%) are recommending DBVT as a Strong Buy, 2 (100%) are recommending DBVT as a Buy, 0 (0%) are recommending DBVT as a Hold, 0 (0%) are recommending DBVT as a Sell, and 0 (0%) are recommending DBVT as a Strong Sell.

If you're new to stock investing, here's how to buy Dbv Technologies Sa stock.

What is DBVT's earnings growth forecast for 2025-2028?

(NASDAQ: DBVT) Dbv Technologies Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Dbv Technologies Sa's earnings in 2025 is -$113,918,000.On average, 1 Wall Street analyst forecast DBVT's earnings for 2025 to be -$746,371,352, with the lowest DBVT earnings forecast at -$746,371,352, and the highest DBVT earnings forecast at -$746,371,352. On average, 1 Wall Street analyst forecast DBVT's earnings for 2027 to be -$725,829,022, with the lowest DBVT earnings forecast at -$725,829,022, and the highest DBVT earnings forecast at -$725,829,022.

In 2028, DBVT is forecast to generate -$342,372,180 in earnings, with the lowest earnings forecast at -$342,372,180 and the highest earnings forecast at -$342,372,180.

What is DBVT's revenue growth forecast for 2025-2027?

(NASDAQ: DBVT) Dbv Technologies Sa's forecast annual revenue growth rate of 55.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Dbv Technologies Sa's revenue in 2025 is $4,151,000.On average, 1 Wall Street analysts forecast DBVT's revenue for 2025 to be $742,262,886, with the lowest DBVT revenue forecast at $742,262,886, and the highest DBVT revenue forecast at $742,262,886. On average, 1 Wall Street analysts forecast DBVT's revenue for 2026 to be $816,215,277, with the lowest DBVT revenue forecast at $816,215,277, and the highest DBVT revenue forecast at $816,215,277.

In 2027, DBVT is forecast to generate $2,393,866,283 in revenue, with the lowest revenue forecast at $2,393,866,283 and the highest revenue forecast at $2,393,866,283.

What is DBVT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: DBVT) forecast ROA is -521.45%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is DBVT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year DBVT price target, the average DBVT price target is $22.50, with the highest DBVT stock price forecast at $35.00 and the lowest DBVT stock price forecast at $10.00.

On average, Wall Street analysts predict that Dbv Technologies Sa's share price could reach $22.50 by Mar 4, 2026. The average Dbv Technologies Sa stock price prediction forecasts a potential upside of 152.53% from the current DBVT share price of $8.91.

What is DBVT's Earnings Per Share (EPS) forecast for 2025-2028?

(NASDAQ: DBVT) Dbv Technologies Sa's current Earnings Per Share (EPS) is -$5.85. On average, analysts forecast that DBVT's EPS will be -$5.45 for 2025, with the lowest EPS forecast at -$5.45, and the highest EPS forecast at -$5.45. On average, analysts forecast that DBVT's EPS will be -$5.30 for 2027, with the lowest EPS forecast at -$5.30, and the highest EPS forecast at -$5.30. In 2028, DBVT's EPS is forecast to hit -$2.50 (min: -$2.50, max: -$2.50).

What is DBVT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: DBVT) forecast ROE is -1,250.13%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.